Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00072969
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2003-11-12
Brief Title:
A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody Daclizumab Versus Antithymocyte Globulin ATG to Treat the Cytopenia of Myelodysplastic Syndrome MDS
Sponsor:
Organization:
National Institutes of Health Clinical Center CC